Canadian Group Calls for Earlier Colorectal Cancer Screening

Published Date: 25 Mar 2026

Modelling shows fewer cases and deaths with screening starting at age 45 years.

Read Full News

Latest News

Too Many Chest CTs for Incidental Lung Nodules?

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

All-Oral Treatment Combo for AML Earns FDA Nod

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

Todays Updates

Hidradenitis Suppurativa Tied to Higher Cardiovascular Risks

Individuals with HS show higher risks for cardiovascular outcomes, including hypertension, coronary or ischemic heart disease, venous thromboembolism, and myocardial infarction, in a meta-analysis.

Todays Updates

Hidradenitis Suppurativa Tied to Higher Cardiovascular Risks

Individuals with HS show higher risks for cardiovascular outcomes, including hypertension, coronary or ischemic heart disease, venous thromboembolism, and myocardial infarction, in a meta-analysis.

Latest News

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

News All Time

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Study Finds Microplastics Near Tumors; Experts Doubt Results

Using LDIR, O PTIR, Py GC/MS, and SEM, researchers quantified MNPs in 191 brain samples, but experts question the unusually high particle masses and urge methodological validation.

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

PSA Screening Overdiagnosis Rises Sharply With Age

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

Can Exercise Extend Survival After Breast Cancer?

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

Photopenia in high CT density renal lesions on [18F]FDG PET/CT scans shows a high negative predictive value for excluding malignancy.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for newly diagnosed acute myeloid leukemia.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.

ICIs Show High Responses in Mediastinal B-Cell Lymphoma

Pembrolizumab and nivolumab show favorable response rates with or without consolidation therapy.

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975

Breast awareness: What to look for in your self-exam

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

3.

Leukemia cells evade treatment by reshaping their mitochondria, researchers discover

4.

Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer

5.

AI could help improve early detection of interval breast cancers

1.

Understanding the Rare Disease: Werner Syndrome Explained

2.

Unlocking the Mystery of Elliptocytes: Exploring the Unusual Shape of Red Blood Cells

3.

The Benefits and Side Effects of Bortezomib in the Fight Against Cancer

4.

A Visual Guide to Understanding Breast Cancer Staging

5.

Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

3.

Navigating the Complexities of Ph Negative ALL - Part I

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

5.

Current Scenario of Cancer- Palliative Care to Close the Care Gap

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Canadian Group Calls for Earlier Colorectal Cancer Screening

Latest News

Too Many Chest CTs for Incidental Lung Nodules?

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

All-Oral Treatment Combo for AML Earns FDA Nod

Low PSA May Not Fully Predict Survival in Prostate Cancer

Only 1 in 4 Eligible Adults Receive Lung Screening

FDA Warns of Secondary Blood Cancer Risk With Tazverik

Todays Updates

Hidradenitis Suppurativa Tied to Higher Cardiovascular Risks

Todays Updates

Hidradenitis Suppurativa Tied to Higher Cardiovascular Risks

Latest News

News All Time

Most NMIBC Recurrences Seen in BCG-Exposed Patients

Study Finds Microplastics Near Tumors; Experts Doubt Results

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

PSA Screening Overdiagnosis Rises Sharply With Age

Can Exercise Extend Survival After Breast Cancer?

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

Can Alternating Venetoclax Regimens Improve AML Outcomes?

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Which Risk Model Better Identifies High-Risk Smoldering MM?

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

ICIs Show High Responses in Mediastinal B-Cell Lymphoma

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

Dasatinib Fails to Improve Outcomes in CBF-AML

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

Recommended News For You

The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.

Only 1 in 4 Eligible Adults Receive Lung Screening